Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Accumulated Expenses (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Other Accumulated Expenses over the past 14 years, most recently at $9.9 million for Q4 2024.

  • For Q4 2024, Other Accumulated Expenses rose 28.85% year-over-year to $9.9 million; the TTM value through Nov 2024 reached $9.9 million, up 28.85%, while the annual FY2024 figure was $9.4 million, 30.97% up from the prior year.
  • Other Accumulated Expenses for Q4 2024 was $9.9 million at Lifecore Biomedical, Inc. \De\, down from $11.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $13.0 million in Q1 2022 and troughed at $3.0 million in Q2 2021.
  • A 5-year average of $7.7 million and a median of $7.4 million in 2023 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 460.6% in 2020 and later tumbled 69.84% in 2021.
  • Year by year, Other Accumulated Expenses stood at $6.1 million in 2020, then tumbled by 36.55% to $3.9 million in 2021, then soared by 141.37% to $9.4 million in 2022, then decreased by 18.24% to $7.7 million in 2023, then grew by 28.85% to $9.9 million in 2024.
  • Business Quant data shows Other Accumulated Expenses for LFCR at $9.9 million in Q4 2024, $11.4 million in Q3 2024, and $9.4 million in Q2 2024.